CY1122631T1 - Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων - Google Patents
Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειωνInfo
- Publication number
- CY1122631T1 CY1122631T1 CY20201100131T CY201100131T CY1122631T1 CY 1122631 T1 CY1122631 T1 CY 1122631T1 CY 20201100131 T CY20201100131 T CY 20201100131T CY 201100131 T CY201100131 T CY 201100131T CY 1122631 T1 CY1122631 T1 CY 1122631T1
- Authority
- CY
- Cyprus
- Prior art keywords
- grbar1
- tgr5
- fxr
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ενώσεις που έχουν ικριώματα χολάνης, με τις εν λόγω ενώσεις για χρήση στη θεραπευτική αγωγή ή/και πρόληψη FΧR και μεσολαβούμενων από ΤGR5/GΡΒΑR1 ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI20140130 | 2014-05-29 | ||
PCT/EP2015/061802 WO2015181275A1 (en) | 2014-05-29 | 2015-05-28 | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122631T1 true CY1122631T1 (el) | 2021-03-12 |
Family
ID=51454763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100131T CY1122631T1 (el) | 2014-05-29 | 2020-02-12 | Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων |
Country Status (24)
Country | Link |
---|---|
US (2) | US10407462B2 (el) |
EP (2) | EP3626725B1 (el) |
JP (1) | JP6820253B2 (el) |
KR (1) | KR102491556B1 (el) |
CN (2) | CN106661079B (el) |
AU (1) | AU2015265893B2 (el) |
CA (1) | CA2948585C (el) |
CY (1) | CY1122631T1 (el) |
DK (2) | DK3626725T3 (el) |
EA (1) | EA032820B1 (el) |
ES (2) | ES2938874T3 (el) |
FI (1) | FI3626725T3 (el) |
HR (2) | HRP20230170T1 (el) |
HU (2) | HUE061506T2 (el) |
LT (2) | LT3626725T (el) |
MA (1) | MA39881B1 (el) |
MX (2) | MX2020004024A (el) |
PH (1) | PH12016502327A1 (el) |
PL (2) | PL3626725T3 (el) |
PT (2) | PT3626725T (el) |
RS (2) | RS59910B1 (el) |
SG (2) | SG10201809362RA (el) |
SI (2) | SI3149019T1 (el) |
WO (1) | WO2015181275A1 (el) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
SI3149019T1 (sl) * | 2014-05-29 | 2020-03-31 | Bar Pharmaceuticals S.R.L. | Derivati holana za uporabo pri zdravljenju in / ali preprečevanju FXR in TGR5 / GPBAR1 posredovanih bolezni |
CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
MX2017005935A (es) | 2014-11-06 | 2018-01-11 | Enanta Pharm Inc | Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos. |
CN111944006B (zh) * | 2014-11-17 | 2021-12-17 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
ES2759725T3 (es) | 2014-11-19 | 2020-05-12 | Nzp Uk Ltd | Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo |
EA033445B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
MX2017006565A (es) | 2014-11-19 | 2018-01-26 | Nzp Uk Ltd | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr). |
KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
AU2016219266A1 (en) | 2015-02-11 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
KR102681304B1 (ko) | 2015-03-31 | 2024-07-03 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유도체 및 이의 이용 방법 |
ES2873088T3 (es) | 2015-06-19 | 2021-11-03 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos para su uso |
JP2018528230A (ja) | 2015-09-24 | 2018-09-27 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 胆汁酸誘導体の調製のための方法および中間体 |
US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3426348B1 (en) | 2016-03-11 | 2021-05-05 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
CN105859817A (zh) * | 2016-05-09 | 2016-08-17 | 成都宇西医药技术有限公司 | 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法 |
GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
WO2017207648A1 (en) | 2016-05-31 | 2017-12-07 | Bionice, S.L.U | Process and intermediates for the preparation of obeticholic acid and derivatives thereof |
EP3464316A4 (en) * | 2016-06-01 | 2020-02-19 | Dr. Reddy's Laboratories Ltd. | PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
IT201600068742A1 (it) * | 2016-07-01 | 2018-01-01 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Derivati dell'acido iodesossicolico e loro uso |
CA3045023A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
KR20220119520A (ko) | 2017-03-28 | 2022-08-29 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
EP3606533B1 (en) * | 2017-04-07 | 2023-11-15 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
CN109021056B (zh) * | 2017-06-09 | 2021-03-09 | 博瑞生物医药(苏州)股份有限公司 | 法尼酯x受体激动剂 |
CN109021055B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药(苏州)股份有限公司 | Fxr激动剂 |
CN109021054B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药(苏州)股份有限公司 | 一种fxr激动剂 |
US11059854B2 (en) * | 2017-07-26 | 2021-07-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing steroid derivative FXR agonist |
EP3705487B1 (en) * | 2017-11-02 | 2022-10-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing cholic acid compound |
PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | Fxrアゴニストの固体形態 |
JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ,インク. | Gpr119アゴニスト |
CN112824425B (zh) * | 2019-11-21 | 2023-10-03 | 成都西岭源药业有限公司 | 一种6-位烯基取代胆酸化合物及其制备方法和应用 |
IT202000008515A1 (it) * | 2020-04-21 | 2021-10-21 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Metodo per la sintesi di un derivato del colano |
CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ,インク. | Ampkアクチベーター |
IT202200011705A1 (it) * | 2022-06-01 | 2023-12-01 | Prec Bio Therapeutics S R L | Derivati del colesterolo e loro usi |
WO2024006537A1 (en) * | 2022-07-01 | 2024-01-04 | Intercept Pharmaceuticals, Inc. | Methods for ameliorating cognitive impairment using bile acid derivatives |
IT202200018669A1 (it) | 2022-09-13 | 2024-03-13 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Combinazioni farmaceutiche comprendenti derivati del colano e loro usi |
WO2024097247A1 (en) * | 2022-10-31 | 2024-05-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
WO2024195903A1 (ko) * | 2023-03-21 | 2024-09-26 | 경희대학교 산학협력단 | 신규한 콜린산 유도체 및 이의 용도 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE433106T1 (de) * | 1998-12-23 | 2009-06-15 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
DE60205891T2 (de) * | 2001-03-12 | 2006-06-22 | Intercept Pharmaceuticals, Inc. | Steroide als agonisten für fxr |
EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
PT2712617T (pt) * | 2004-03-12 | 2017-02-13 | Intercept Pharmaceuticals Inc | Tratamento de fibrose usando ligandos fxr |
ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
WO2008002573A2 (en) * | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
US8940719B2 (en) * | 2006-07-03 | 2015-01-27 | Academia Sinica | Lithocholic acid analogues that inhibit sialyltransferase |
FR2908310B1 (fr) * | 2006-11-14 | 2009-07-10 | Phytodia | Produits agonistes de tgr5 et leurs applications |
EP1947108A1 (en) * | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
CA2676417C (en) * | 2007-01-19 | 2016-06-28 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
US8796249B2 (en) * | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
ES2774368T3 (es) * | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
LT2698375T (lt) * | 2008-11-19 | 2018-07-10 | Intercept Pharmaceuticals, Inc. | Tgr5 moduliatoriai ir jų panaudojimo būdas |
EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
US20130261317A1 (en) * | 2010-09-27 | 2013-10-03 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
US20130034536A1 (en) | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis |
US9238673B2 (en) * | 2012-06-19 | 2016-01-19 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
EP2912013B1 (en) * | 2012-10-26 | 2017-10-11 | Intercept Pharmaceuticals, Inc. | Process for preparing bile acid derivatives |
US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
CN103143021A (zh) * | 2013-03-21 | 2013-06-12 | 中国药科大学 | PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用 |
PE20160665A1 (es) * | 2013-05-14 | 2016-08-07 | Intercept Pharmaceuticals Inc | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x |
CA2920017C (en) * | 2013-08-01 | 2021-11-23 | Frank J. Gonzalez | Inhibitors of the farnesoid x receptor and uses in medicine |
WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
SI3149019T1 (sl) | 2014-05-29 | 2020-03-31 | Bar Pharmaceuticals S.R.L. | Derivati holana za uporabo pri zdravljenju in / ali preprečevanju FXR in TGR5 / GPBAR1 posredovanih bolezni |
US20170233431A1 (en) * | 2016-02-17 | 2017-08-17 | City Of Hope | Bile acid derivatives and methods for synthesis and use |
-
2015
- 2015-05-28 SI SI201531091T patent/SI3149019T1/sl unknown
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/zh active Active
- 2015-05-28 EA EA201692316A patent/EA032820B1/ru unknown
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/en active Application Filing
- 2015-05-28 ES ES19204247T patent/ES2938874T3/es active Active
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 MA MA39881A patent/MA39881B1/fr unknown
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/ko active IP Right Grant
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/hu unknown
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/pl unknown
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 PL PL15731260T patent/PL3149019T3/pl unknown
- 2015-05-28 SI SI201531924T patent/SI3626725T1/sl unknown
- 2015-05-28 MX MX2020004024A patent/MX2020004024A/es unknown
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/zh active Active
- 2015-05-28 RS RS20200163A patent/RS59910B1/sr unknown
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/da active
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/en active Active
- 2015-05-28 MX MX2016015724A patent/MX2016015724A/es active IP Right Grant
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/hu unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/pt unknown
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/lt unknown
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/lt unknown
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/ja active Active
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/fi active
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/hr unknown
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/da active
- 2015-05-28 RS RS20230132A patent/RS64050B1/sr unknown
- 2015-05-28 PT PT157312604T patent/PT3149019T/pt unknown
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/en active Active
- 2015-05-28 ES ES15731260T patent/ES2768718T3/es active Active
- 2015-05-28 CA CA2948585A patent/CA2948585C/en active Active
-
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
-
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
-
2020
- 2020-02-11 HR HRP20200225TT patent/HRP20200225T1/hr unknown
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122631T1 (el) | Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων | |
CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CY1123603T1 (el) | Αγωγη κακοηθειων β-κυτταρων μεσω συνδυασμου jak και ρι3κ αναστολεα | |
CY1121653T1 (el) | C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1124886T1 (el) | Χιμαιρικοι υποδοχεις αντιγονου bcma | |
CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
DOP2016000173A (es) | Heteroarilos y usos de estos | |
MA53399A (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
EA201790575A1 (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
CY1123920T1 (el) | Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου | |
BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
CY1124406T1 (el) | Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης | |
DK3865484T3 (da) | Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
DK3236983T3 (da) | Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet | |
DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
MA43052A (fr) | Inhibiteurs de la kallicréine plasmatique humaine |